Literature DB >> 25111481

Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness.

Mathilde Cheray1, Arulraj Nadaradjane, Pascal Bonnet, Sylvain Routier, François M Vallette, Pierre-François Cartron.   

Abstract

AIM: DNA methylation is a fundamental biologic process of genomes and is a candidate for pharmacological manipulation that might have important therapeutic advantages. Thus, DNA methyltransferases (DNMTs) appear to be ideal targets for drug intervention. MATERIALS &
METHODS: To develop a new generation of DNMT inhibitor, we analyzed the ability of peptides to selectively inhibit certain DNMT1-incuding complexes.
RESULTS: Our study demonstrates that the disruption of DNMT1/CFP1-including complexes increases the efficiency of chemotherapeutic treatment on established tumors in mice.
CONCLUSION: Our data opens a promising and innovative alternative to the development of DNMT inhibitors.

Entities:  

Keywords:  DNA methylation; DNMT inhibitor; DNMT1; cell death; epigenetic; glioblastoma; glioma

Mesh:

Substances:

Year:  2014        PMID: 25111481     DOI: 10.2217/epi.14.18

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  7 in total

Review 1.  Epigenome-modifying tools in asthma.

Authors:  Peter O Brook; Mark M Perry; Ian M Adcock; Andrew L Durham
Journal:  Epigenomics       Date:  2015-10-07       Impact factor: 4.778

Review 2.  Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma.

Authors:  Eric Hervouet; Paul Peixoto; Régis Delage-Mourroux; Michaël Boyer-Guittaut; Pierre-François Cartron
Journal:  Clin Epigenetics       Date:  2018-02-09       Impact factor: 6.551

Review 3.  DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.

Authors:  Omar Castillo-Aguilera; Patrick Depreux; Ludovic Halby; Paola B Arimondo; Laurence Goossens
Journal:  Biomolecules       Date:  2017-01-05

4.  miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker.

Authors:  Arulraj Nadaradjane; Joséphine Briand; Gwenola Bougras-Cartron; Valentine Disdero; François M Vallette; Jean-Sébastien Frenel; Pierre-François Cartron
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-13       Impact factor: 8.886

5.  Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation.

Authors:  Joséphine Briand; Arulraj Nadaradjane; Gwenola Bougras-Cartron; Christophe Olivier; François M Vallette; Pierre-François Cartron
Journal:  Clin Epigenetics       Date:  2019-11-14       Impact factor: 6.551

6.  Misregulation of the expression and activity of DNA methyltransferases in cancer.

Authors:  Isaiah K Mensah; Allison B Norvil; Lama AlAbdi; Sarah McGovern; Christopher J Petell; Ming He; Humaira Gowher
Journal:  NAR Cancer       Date:  2021-12-01

7.  Specific Inhibition of DNMT3A/ISGF3γ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth.

Authors:  Mathilde Cheray; Romain Pacaud; Arulraj Nadaradjane; Lisa Oliver; François M Vallette; Pierre-François Cartron
Journal:  Theranostics       Date:  2016-08-25       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.